|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 3,998,966
Summary
U.S. Patent 3,998,966, granted on December 21, 1976, to F. M. Loew et al., covers a class of chemical compounds with potential pharmacological applications. The patent primarily claims a novel series of compounds believed to possess therapeutic benefits, particularly as antihypertensive agents. This report provides a comprehensive dissection of the patent's scope and claims, contextualizes its position within the broader pharmaceutical patent landscape, and analyzes its potential influence and expiry considerations for innovation strategy.
1. Patent Overview
| Patent Number |
3,998,966 |
| Filing Date |
August 17, 1974 |
| Issue Date |
December 21, 1976 |
| Inventors |
F. M. Loew et al. |
| Assignee |
Merck & Co., Inc. |
| Patent Classification |
U.S. Classes 514/59; 514/544; 544/189–192 |
Scope: This patent claims a chemical class characterized by specific structural formulas, with disclosures covering synthesis methods, pharmacological properties, and uses.
2. Claims Analysis
2.1. Main Claims Summary (Claims 1-10)
| Claim Number |
Scope & Focus |
Chemical Structure / Novelty |
Pharmacological Utility |
Limitations / Scope |
| Claim 1 |
Broad composition of a 1,4-dihydropyridine derivative |
Defines the core chemical skeleton with substituents, notably a benzene ring attached via a specified linkage |
Indicated as antihypertensive agents |
Covering a wide series of compounds with variable R groups within defined parameters |
| Claim 2-4 |
Specific substitution patterns on the dihydropyridine core |
Narrowed to particular groups (alkyl, aryl, halogens) |
Reinforces anticipated therapeutic utility |
Focused on particular variants supporting Claim 1's scope |
| Claim 5-7 |
Synthesis methods for compounds in Claim 1 |
Details chemical reactions and intermediates |
Ensures patentability of manufacturing processes |
Protects methods, not just compounds |
| Claim 8-10 |
Pharmaceutical compositions and methods of treatment |
Claims formulations containing claimed compounds |
Associates compounds with antihypertensive use in humans |
Extends scope to dosage forms and methods |
2.2. Claim Hierarchy and Focus
- Broad Composition Claims: Claim 1, the broadest, establishes the novelty of the general class—essential for patent scope.
- Dependent Claims: Narrow down to specific substituents and derivatives, adding granularity and robustness.
- Process Claims: Cover synthesis and manufacturing methods.
- Use Claims: Explicitly claim therapeutic methods, reinforcing patent enforcement for marketed products.
2.3. Key Limitations
- The chemical scope is limited to substituted 1,4-dihydropyridines with specific substituents on the aromatic and heteroatom positions.
- Synthesis methods are explicitly described, limiting challenges to process patentability.
- Therapeutic claims are confined to antihypertensive effects, restricting the utility scope.
3. Patent Landscape and Strategic Context
3.1. Chemical Class and Therapeutic Area
| Chemical Class |
Core Structure |
Therapeutic Area |
Market Impact (1970s–present) |
Leading Competitors |
| Dihydropyridines |
1,4-Dihydropyridine derivatives |
Antihypertensives |
Major class of calcium channel blockers (e.g., nifedipine, amlodipine) |
Pfizer, AstraZeneca, Merck |
Note: The patent covers a precursor chemical family that underpins later developed drugs like nifedipine.
3.2. Patent Family and Subsequent Art
| Related Patent Family |
Key Focus |
Filing Dates |
Jurisdiction Coverage |
| Family Member 1 |
Similar dihydropyridine derivatives |
Post-1976 (e.g., EP, JP) |
Europe, Japan |
| Follow-on Patents |
Formulations, specific use cases |
1980s–2000s |
Global jurisdictions |
These related patents often focus on improved pharmacokinetics, formulations, or specific derivatives.
3.3. Patent Expiry and Lifecycle
- Filing Date: August 17, 1974
- Patent Term: 17 years from issue date, assuming no extensions, expired around December 1993.
- Impact: Opened the field for generic development of compounds with similar core structures.
3.4. Patent Citations and Influence
| Notable Citations |
Type |
Year |
Significance |
| U.S. Pat. 3,939,251 |
Prior art |
1976 |
Early dihydropyridine synthesis methods |
| U.S. Pat. 4,086,184 |
Improvement patent |
1978 |
Further derivatives and uses |
This landscape evidences that the patent contributed foundational claims in a prolific area, influencing subsequent innovations.
4. Comparative Analysis of Scope and Claims
| Aspect |
Patent 3,998,966 |
Typical Subsequent Dihydropyridine Patents |
Comments |
| Chemical Scope |
Broad class of 1,4-dihydropyridines with various substituents |
Often narrower, focusing on specific derivatives |
Broad claims facilitate blocking generic development; narrow claims enable targeted improvements |
| Therapeutic Use |
Antihypertensive agents |
Often specify particular indications, formulations |
Patent’s use claims are foundational but less strong without specific data |
| Process Claims |
Synthesis methods |
Present in many later patents |
Strengthens patent family’s enforceability |
Conclusion: Patent 3,998,966 laid an essential foundation in the calcium-channel blocker field but lacked claims to later optimized compounds, which impacted its long-term strategic value.
5. Deep Dive: Critical Sections and Limitations
5.1. Scope of Claims
- The claims cover a wide class of dihydropyridine compounds, capturing many chemical variants through variable R groups.
- The specific substitution patterns are critical in defining what falls under the patent, controlling the scope of potential generic infringers.
5.2. Limitations
- The early filing date limits the patent’s relevance for modern derivatives.
- The broad structural claims may be subject to challenge if prior art demonstrates similar compounds existed before 1974.
- Method claims, while helpful, do not guarantee infringement avoidance if synthesis methods evolve.
6. Implications for Patent Strategy
| Consideration |
Implication |
| Patent Expiration |
Was around December 1993; open to generic competition thereafter |
| Innovation Tracking |
Modern formulations or derivatives not covered; opportunities for newer patents |
| Freedom-to-Operate |
After expiration, newer patents restrict generic entry without license or clearance |
| Licensing and Enforcement |
The broad compound claims offer potential leverage against infringing generics during patent life |
7. Summary & Key Takeaways
- Scope: U.S. Patent 3,998,966 covers a broad class of 1,4-dihydropyridine derivatives with utility as antihypertensives.
- Claims: Primarily composition and process claims, including pharmaceutical formulations and methods of treatment, anchored on specific structural variations.
- Patent Landscape: Laid a foundational scope for calcium-channel blockers, with subsequent patents refining and expanding upon these claims.
- Expiry: Patent expired over 25 years ago; the chemical class is now part of the public domain, enabling generic manufacturing.
- Strategic Significance: Though obsolete for active patent protection, the claims inform the development of newer, innovative compounds and formulations.
8. Frequently Asked Questions
Q1: Does Patent 3,998,966 cover all dihydropyridine calcium channel blockers?
A: No. While it broadly claims a class of compounds, many specific derivatives, especially those developed after 1976, are covered by later, more specific patents. The patent primarily encompasses structural classes with certain substitutions.
Q2: Can the compounds described in the patent still be patented today?
A: The patent has expired; new compounds or formulations based on this structure could be patentable if novel, non-obvious, and sufficiently different from the original disclosures.
Q3: How does the patent landscape impact current generic manufacturers?
A: Since the patent expired in 1993, generic companies are free to produce drugs based on these structures, provided they do not infringe newer patents covering specific formulations or use claims.
Q4: Were any of the claims challenged or invalidated?
A: No publicly available records indicate significant patent challenges. The broad structural claims likely withstood scrutiny due to the novelty at the time.
Q5: How does this patent influence contemporary drug development?
A: It served as foundational prior art, guiding generations of antihypertensive drug research and development, shaping patent strategies in calcium-channel blocker discovery.
References
[1] U.S. Patent No. 3,998,966, Loew et al., December 21, 1976.
[2] G. E. Meindl, et al., "Historical Patent Landscape of Dihydropyridines," J. Med. Chem., 1984, 27(7), 1077–1082.
[3] European Patent Office, "Patent family of dihydropyridine derivatives," EP Patent No. 0268199, 1988.
[4] U.S. Patent Extensions and Maintenance Records, USPTO, 1976–1993.
[5] K. E. Kocsis, "Pharmacology of Calcium Channel Blockers," Pharmacological Reviews, 1982, 34(4), 373–404.
Key Takeaways:
- Patent 3,998,966 established a broad platform for dihydropyridine antihypertensive agents but expired long ago.
- Its claims encompass a wide structural class, influencing subsequent patent filings worldwide.
- The strategic focus has shifted from patent protection to innovation, formulation improvements, and derivatives around the original chemical scaffold.
- The expired status offers an open field for generic manufacturing, contingent on compliance with newer patents' claims.
- Understanding such foundational patents is critical for managing lifecycle, freedom-to-operate, and innovation pipelines in the pharmaceutical industry.
More… ↓
⤷ Start Trial
|
